



PATENT  
ATTORNEY DOCKET: 59046.000044

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application Number : 10/733,488 Confirmation No.: 7675  
Applicant : Yaron Ilan et al.  
Filed : 12/10/2003  
Title : REGULATION OF IMMUNE RESPONSES BY MANIPULATION  
OF ITERMEDIARY METABOLITE LEVELS  
TC/Art Unit : 1648  
Examiner: : Emily M. Le  
  
Docket No. : 59046.000044  
Customer No. : **21967**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, and in compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56, applicants submit attached Form PTO-SB/08A (modified) for consideration and request the references cited therein be made of record by the U.S. Patent and Trademark Office in the above-captioned application.

Consideration of the foregoing plus the prompt return of a copy of the enclosed Form SB/08A with the Examiner's initials in the left column in accordance with MPEP 609 are respectfully requested.

This Information Disclosure Statement is being submitted after the mailing of a non-final Office Action, but is believed to be prior to a final Office Action or a Notice of Allowance. Pursuant to 37 C.F.R. § 1.97(c)(2), a check in the amount of \$180.00 as set forth in § 1.17(p) is enclosed. In the event any variance exists between the amount enclosed and the

Patent Office charges, please charge or credit any difference to the undersigned's Deposit Account No. 50-0206.

Respectfully submitted,

HUNTON & WILLIAMS LLP


Dated: August 23, 2006

By: 

Robert M. Schulman  
Registration No. 31,196

Sheridan K. Snedden  
Registration No. 55,998

Hunton & Williams LLP  
Intellectual Property Department  
1900 K Street, N.W.  
Suite 1200  
Washington, DC 20006  
(202) 955-1500 (telephone)  
(202) 778-2201 (facsimile)  
RMS/RCL/SKS:gjc



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	10/733,488
Filing Date	December 10, 2003
First Named Inventor	Yaron Ilan et al.
Art Unit	1648
Examiner Name	Emily M. Le
Attorney Docket Number	59046.000044

Sheet 1 of 1

**U.S. PATENT DOCUMENTS**

*Examiner Initials	Cite No.	DOCUMENT NUMBER Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- 2004/0171522	09-02-2004	Ilan et al.	
		US- 2004/0171557	09-02-2004	Ilan et al.	
		US- 2004/0171527	09-02-2004	Ilan et al.	
		US- 2004/0171528	09-02-2004	Ilan et al.	
		US- 2003/0170258	09-11-2003	Roy-Chowdhury et al.	
		US- 2004/0022768	02-05-2004	Roy-Chowdhury et al.	

**FOREIGN PATENT DOCUMENTS**

*Examiner Initial	Cite No.	FOREIGN PATENT DOCUMENT	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
		Country Code Number-Kind Code (if known)				YES	NO
						<input type="checkbox"/>	<input type="checkbox"/>

**OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS**

		U.S. Patent Application No. 11/378,941 filed March 17, 2006.	<input type="checkbox"/>	<input type="checkbox"/>
		Takahashi M, Nakamura K, Honda K, Kitamura Y, Mizutani T, Araki Y, Kabemura T, Chijiwa Y, Harada N, Nawata H., "An inverse correlation of human peripheral blood regulatory T cell frequency with the disease activity of ulcerative colitis." Dig Dis Sci. 2006 Apr. 51(4):677-86. (ABSTRACT only.)	<input type="checkbox"/>	<input type="checkbox"/>
		Bode JG, Ludwig S, Ehrhardt C, Albrecht U, Erhardt A, Schaper F, Heinrich PC, Haussinger D., "IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3." FASEB J. 2003 Mar;17(3):488-90. Epub 2003 Jan 22.	<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER SIGNATURE

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.